Share on LinkedInShare on LinkedIn

ARTICLE · 08 APRIL 2010

The Turkish Pharmaceutical Industry: Anti-trust Developments In 2009.

Gün + Partners
Gün + Partners
Contributor
Gün + Partners

Gün + Partners

We are one of the oldest and largest law firms in Turkey and are considered internationally to be...

View firm profile
Explore more from Gün + Partners

The pharmaceutical industry has been a constant source of antitrust focus in recent years. This report intends to give an outline of major developments in Turkish competition law and practice in 2009 with a particular focus on the industry.

TurkeyAntitrust/Competition Law

Executive Summary

The pharmaceutical industry has been a constant source of antitrust focus in recent years. This report intends to give an outline of major Turkish competition law developments in 2009 with a particular focus on the pharmaceutical industry.

The Sector Inquiry

On January 20th, 2009, the Turkish Competition Authority ("TCA") initiated a sector inquiry in the pharmaceutical sector to identify any lack of or distortion to competition in the market. The TCA declared that their inquiry will have a broader scope than the sector inquiry in the EU and include an analysis of pricing, reimbursement, market entry conditions, distribution channels and public procurement processes in addition to the analysis of potential delays in generic entry, decline in the number of new medicines, and the use of intellectual property rights.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from